Objective To assess the role of 68Ga-N, N′-bis(2-hydroxy-5-(carboxyethyl)benzyl) ethylenediamine-N, N′-diacetic acid(HBED-CC)-(Ahx)Lys-CO-Glu(PSMA-11) PET/CT on the detection of metastatic lesions from castration-resistant prostate cancer (CRPC). Methods Sixteen patients with CRPC who underwent 68Ga-PSMA-11 PET/CT between January 2015 and November 2015 were recruited in this study. Mean age of patients was (72±9) years. The PSA levels were 4-12 356 μg/L, Gleason score was 7-10. PET/CT was performed at 1 h postinjection of 68Ga-PSMA-11. Patient-based analysis and lesion-based analysis were performed. ROI analysis was used to calculate the tumor uptake (SUVmax). Final diagnosis was based on histopathology and results of other imaging examinations(99Tcm-MDP imaging, MRI). χ2 test was used to compare the diagnostic efficiencies of PET and CT. Results No adverse effects were observed in patients. 68Ga-PSMA-11 PET/CT showed moderate physiologic uptake in salivary glands and proximal small intestine, with predominant tracer clearance by the kidneys. All patients were positive on 68Ga-PSMA-11 PET/CT. Bone metastasis was found in 16 patients, liver metastasis in 2 patients (5 lesions), and lymph node metastasis in 4 patients (26 lesions). The SUVmax of liver, lymph node and bone metastases were 15.06±2.77, 7.54±5.20, 19.01±16.96, respectively. The diagnostic sensitivity, specificity and accuracy on bone metastasis with 68Ga-PSMA-11 PET and CT were 96.30%(52/54) vs 61.11%(33/54), 3/3 vs 1/3, 96.49%(55/57) vs 59.65%(34/57). The sensitivities and accuracies of the two modalities were significantly different(χ2=19.943, 22.593, both P<0.01). Conclusions 68Ga-PSMA-11 PET/CT could precisely detect both primary and metastatic lesions of CRPC, suggesting that it is of great value for the clinical management and treatment. Key words: Prostatic neoplasms, castration-resistant; Positron-emission tomography; Tomography, X-ray computed; Prostate-specific membrane antigen; Gallium radioisotopes